Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study STARTReport as inadecuate




Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study START - Download this document for free, or read online. Document in PDF available to download.

Journal of Cancer Research and Clinical Oncology

, Volume 140, Issue 2, pp 319–328

First Online: 24 December 2013Received: 28 September 2013Accepted: 28 November 2013DOI: 10.1007-s00432-013-1563-5

Cite this article as: Koizumi, W., Kim, Y.H., Fujii, M. et al. J Cancer Res Clin Oncol 2014 140: 319. doi:10.1007-s00432-013-1563-5

Abstract

PurposeCisplatin plus 5-fluorouracil has been globally accepted as a standard regimen for the treatment for advanced gastric cancer. However, cisplatin has several disadvantages, including renal toxicity and the need for admission. S-1 plus cisplatin has become a standard treatment for advanced gastric cancer in East Asia. This phase III study was designed to evaluate the potential benefits of adding docetaxel to S-1 without a platinum compound in patients with advanced gastric cancer.

MethodsPatients were randomly assigned to receive docetaxel plus S-1 or S-1 alone. The docetaxel plus S-1 group received docetaxel on day 1 and oral S-1 on days 1–14 of a 21-day cycle. The S-1 alone group received oral S-1 on days 1–28 of a 42-day cycle. The primary end point was overall survival.

ResultsOf the 639 patients enrolled, 635 were eligible for analysis. The median overall survival was 12.5 months in the docetaxel plus S-1 group and 10.8 months in the S-1 alone group p = 0.032. The median progression-free survival was 5.3 months in the docetaxel plus S-1 group and 4.2 months in the S-1 alone group p = 0.001. As for adverse events, neutropenia was more frequent in the docetaxel plus S-1 group, but remained manageable.

ConclusionAs first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone. ClinicalTrials.gov number: NCT00287768.

KeywordsAdvanced gastric cancer Chemotherapy S-1 Docetaxel  Download fulltext PDF



Author: Wasaburo Koizumi - Yeul Hong Kim - Masashi Fujii - Hoon Kyo Kim - Hiroshi Imamura - Kyung Hee Lee - Takuo Hara - Hyun C

Source: https://link.springer.com/







Related documents